X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (35) 35
index medicus (33) 33
female (27) 27
male (27) 27
oncology (24) 24
adolescent (22) 22
adult (21) 21
cancer (20) 20
young adult (18) 18
neoplasms - psychology (14) 14
quality of life (14) 14
neoplasms - therapy (13) 13
abridged index medicus (12) 12
outcomes (12) 12
aged (11) 11
middle aged (11) 11
survivors (11) 11
survivors - psychology (11) 11
young adults (11) 11
quality-of-life (10) 10
article (9) 9
breast-cancer (9) 9
child (9) 9
risk factors (9) 9
care and treatment (8) 8
surveys and questionnaires (7) 7
teenagers (7) 7
childhood-cancer (6) 6
diagnosis (6) 6
health (6) 6
health status (6) 6
impact (6) 6
long-term survivors (6) 6
children (5) 5
double-blind method (5) 5
fertility preservation (5) 5
health aspects (5) 5
research (5) 5
social support (5) 5
symptoms (5) 5
united states (5) 5
youth (5) 5
analysis (4) 4
cancer patients (4) 4
cancer survivors (4) 4
cardiovascular disease (4) 4
cardiovascular diseases (4) 4
cardiovascular diseases - mortality (4) 4
care (4) 4
clinical trials (4) 4
diabetes (4) 4
diabetes mellitus, type 2 - drug therapy (4) 4
epidemiology (4) 4
health services accessibility (4) 4
heart attacks (4) 4
heart failure (4) 4
medicine & public health (4) 4
medicine, general & internal (4) 4
mortality (4) 4
myocardial infarction (4) 4
neoplasms - diagnosis (4) 4
pediatrics (4) 4
psychosocial (4) 4
risk (4) 4
stroke (4) 4
survivor (4) 4
survivorship (4) 4
type 2 diabetes (4) 4
uracil - analogs & derivatives (4) 4
acute coronary syndrome (3) 3
adolescent and young adult (3) 3
adolescents (3) 3
adults (3) 3
cancer care (3) 3
cerebral infarction (3) 3
child, preschool (3) 3
cross-sectional studies (3) 3
diabetes mellitus, type 2 - complications (3) 3
drug therapy (3) 3
heart-failure (3) 3
hematology (3) 3
hospitalization (3) 3
humanities (3) 3
hypoglycemic agents - therapeutic use (3) 3
infant (3) 3
longitudinal studies (3) 3
mellitus (3) 3
multivariate analysis (3) 3
needs (3) 3
neoplasms (3) 3
neoplasms - mortality (3) 3
patient outcomes (3) 3
patients (3) 3
piperidines - therapeutic use (3) 3
proportional hazards models (3) 3
psychiatry (3) 3
psychological aspects (3) 3
psychological distress (3) 3
quality of life - psychology (3) 3
quality of life research (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 09/2017, Volume 377, Issue 12, pp. 1119 - 1131
Patients with myocardial infarction and a high-sensitivity CRP level of 2 mg or more per liter were assigned to one of three canakinumab doses or placebo. The... 
C-REACTIVE PROTEIN | MEDICINE, GENERAL & INTERNAL | HEART-DISEASE | MYOCARDIAL-INFARCTION | STATIN THERAPY | CLONAL HEMATOPOIESIS | INFLAMMATION | CARDIOVASCULAR-DISEASE | INTERLEUKIN-1-BETA INHIBITION | RISK | CORONARY-ARTERY-DISEASE | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Male | Secondary Prevention | Infection - etiology | Incidence | Dose-Response Relationship, Drug | Anti-Inflammatory Agents - adverse effects | C-Reactive Protein - metabolism | Lipids - blood | Cardiovascular Diseases - epidemiology | Cardiovascular Diseases - mortality | Anti-Inflammatory Agents - administration & dosage | Female | Neutropenia - chemically induced | Interleukin-1beta - antagonists & inhibitors | Stroke - prevention & control | Atherosclerosis - drug therapy | Double-Blind Method | Interleukin-1beta - immunology | Atherosclerosis - blood | Myocardial Infarction - drug therapy | Antibodies, Monoclonal - administration & dosage | Aged | Myocardial Infarction - prevention & control | Myocardial infarction | Cerebral infarction | Stroke | Heart attacks | C-reactive protein | Cytokines | Clinical trials | Cardiovascular disease | Innate immunity | Inflammation | Angina | Angina pectoris | Thrombosis | Cholesterol | Disease prevention | Proteins | Arteriosclerosis | Atherosclerosis | Cardiovascular diseases | Health risk assessment | Drug therapy | Drug dosages | Klinisk medicin | Clinical Medicine
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 10/2013, Volume 369, Issue 14, pp. 1327 - 1335
Alogliptin, a new antihyperglycemic agent of the DPP-4 class, was shown to have no significant effect on cardiovascular risk over a median treatment period of... 
INHIBITOR ALOGLIPTIN | MEDICINE, GENERAL & INTERNAL | CARDIOVASCULAR SAFETY | MELLITUS | OUTCOMES | MYOCARDIAL-INFARCTION | Hypoglycemic Agents - therapeutic use | Double-Blind Method | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Glycated Hemoglobin A - metabolism | Humans | Middle Aged | Uracil - therapeutic use | Male | Myocardial Infarction - complications | Myocardial Infarction - drug therapy | Uracil - adverse effects | Angina, Unstable - drug therapy | Piperidines - therapeutic use | Angina, Unstable - complications | Piperidines - adverse effects | Cardiovascular Diseases - mortality | Female | Aged | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Diabetes Mellitus, Type 2 - complications | Uracil - analogs & derivatives | Type 2 diabetes | Care and treatment | Acute coronary syndrome | Patient outcomes | Risk factors | Myocardial infarction | Heart attacks | Cardiovascular disease | Angina | Drug development | Hemoglobin | Diabetes mellitus (non-insulin dependent) | Drug dosages | Cerebral infarction | Stroke | Peptidase | Statistical analysis | Diabetes mellitus | Pancreatitis | Committees | FDA approval | Hypoglycemia | Angina pectoris | Studies | Product development | Diabetes | Acute coronary syndromes | Cardiovascular diseases | Health risk assessment | Cancer
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2019, Volume 380, Issue 4, pp. 347 - 357
In a randomized trial of patients with type 2 diabetes, treatment with dapagliflozin, an SGLT2 inhibitor that promotes glucosuria, did not result in a higher... 
2013 ACCF/AHA GUIDELINE | MEDICINE, GENERAL & INTERNAL | SELECTIVE SGLT2 INHIBITOR | MANAGEMENT | HEART-FAILURE OUTCOMES | DISEASE | AMERICAN-COLLEGE | ASSOCIATION TASK-FORCE | KIDNEY | EMPAGLIFLOZIN | SOCIETY | Cardiovascular Diseases - etiology | Sodium-Glucose Transporter 2 Inhibitors - therapeutic use | Sodium-Glucose Transporter 2 Inhibitors - adverse effects | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Hospitalization - statistics & numerical data | Male | Benzhydryl Compounds - adverse effects | Cardiovascular Diseases - mortality | Female | Glucosides - therapeutic use | Aged | Diabetes Mellitus, Type 2 - drug therapy | Benzhydryl Compounds - therapeutic use | Heart Failure - epidemiology | Diabetes Mellitus, Type 2 - complications | Glucosides - adverse effects | Type 2 diabetes | Safety and security measures | Dapagliflozin | Dosage and administration | Drug therapy | Cardiovascular diseases | Risk factors | Heart failure | Myocardial infarction | Cerebral infarction | End-stage renal disease | Heart attacks | Mortality | Diabetes mellitus | Cardiovascular disease | FDA approval | Patients | Glomerular filtration rate | Heart rate | Ischemia | Sodium | Arteriosclerosis | Ketoacidosis | Death | Diabetes | Kidney diseases | Safety | Diabetes mellitus (non-insulin dependent) | Heart diseases | Cardiovascular Diseases | drug therapy | Benzhydryl Compounds | complications | Sodium-Glucose Transporter 2 Inhibitors | Hospitalization | prevention & control | Klinisk medicin | Diabetes Mellitus | etiology | Clinical Medicine | epidemiology | statistics & numerical data | adverse effects | mortality | Type 2 | Heart Failure | therapeutic use | Glucosides
Journal Article